June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Diagnostic ramifications of ocular vascular occlusion as a first thrombotic event associated with Factor V Leiden and Prothrombin Gene heterozygosity
Author Affiliations & Notes
  • Samantha Schockman
    Internal Medicine Residency Program at The Jewish Hospital - Mercy Health, Cincinnati, OH
  • Charles J Glueck
    The Cholesterol, Metabolism, and Thrombosis Center of the Jewish Hospital, Cincinnati, OH
    Mercy Medical Physicians, Cincinnati, OH
  • Robert K Hutchins
    Cincinnati Eye Institute, Cincinnati, OH
    Department of Ophthalmology, University of Cincinnati College of Medicine, Cincinnati, OH
  • Ping Wang
    The Cholesterol, Metabolism, and Thrombosis Center of the Jewish Hospital, Cincinnati, OH
  • Footnotes
    Commercial Relationships Samantha Schockman, None; Charles J Glueck, None; Robert K Hutchins, None; Ping Wang, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 209. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Samantha Schockman, Charles J Glueck, Robert K Hutchins, Ping Wang; Diagnostic ramifications of ocular vascular occlusion as a first thrombotic event associated with Factor V Leiden and Prothrombin Gene heterozygosity. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):209.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

Assess the diagnostic ramifications of ocular vascular occlusion (OVO) as a first thrombotic event associated with factor V Leiden (FVL) and/or Prothrombin Gene (PTG) heterozygosity.

 
Methods
 

Patients with OVO, free of cardio-embolic etiologies (n=264), were sequentially referred from vitreoretinal specialists for measurement of thrombophilia-hypofibrinolysis, and compared to 111 healthy normal controls.

 
Results
 

Of the 264 patients, 27 (15 women, 12 men), 10% of all referred OVO cases, were found to have familial thrombophilias (FVL and/or PTG), including 15 with FVL, 11 PTG, and 1 with both FVL and PTG. Compared to controls, the 264 cases were marginally more likely to have ≥1 abnormality of FVL and/or PTG mutation (10% vs 5%, p=.071). Patients with OVO, compared to controls, were more likely to have low free protein S (9% vs 2%, p=.048), high homocysteine (21% vs 5%, p<.0001), high Factor VIII (19% vs 7%, p=.007), and high anticardiolipin IgM antibody (ACLA IgM) (8% vs 2%, p=.027). Of the 264 cases, 48% had ≥1 thrombophilic abnormality (FVL, PTG, free protein S, homocysteine, factors VIII and XI, and/or ACLA IgM), vs 19% of normal controls, p<.0001. Of the 27 cases with FVL and/or PTG, 15 had central retinal vein occlusion (CRVO), 5 non-arteritic anterior ischemic optic neuropathy (NAION), 4 central retinal artery occlusion (CRAO), 2 amaurosis fugax (AF) and 1 had both CRVO and CRAO. Of the 15 FVL cases, 14 (93%) had OVO as a first thrombotic event without prior DVT or PE, 5 (33%) had other thrombotic events including recurrent miscarriages, osteonecrosis, ischemic stroke and/or ischemic colitis, and 5 (33%) had immediate family members with previous venous thromboembolism (VTE). Of the 11 PTG cases, 8 (73%) had OVO as a first thrombotic event, 5 (45%) experienced VTE other than DVT or PE, and 5 (45%) had immediate family members with VTE. In 1 patient with both FVL and PTG, DVT occurred before CRVO. Of the 15 women with FVL and/or PTG mutations, 7 (47%) experienced ≥1 miscarriage, 4 (27%) were on estrogen, and 1 (7%) was on Clomiphene.

 
Conclusions
 

Of the 264 patients with OVO, 27 (10%) had FVL and/or PTG, and 81% of these cases presented with OVO as their first thrombotic event. By diagnosing thrombophilia as an etiology for OVO, the ophthalmologist opens a window to family screening and preventive therapy.  

 

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×